These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 30155446)

  • 21. Latent TB Infection (LTBI) - Mycobacterium tuberculosis pathogenesis and the dynamics of the granuloma battleground.
    Rao M; Ippolito G; Mfinanga S; Ntoumi F; Yeboah-Manu D; Vilaplana C; Zumla A; Maeurer M
    Int J Infect Dis; 2019 Mar; 80S():S58-S61. PubMed ID: 30822547
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pasakbumin A controls the growth of Mycobacterium tuberculosis by enhancing the autophagy and production of antibacterial mediators in mouse macrophages.
    Lee HJ; Ko HJ; Kim SH; Jung YJ
    PLoS One; 2019; 14(3):e0199799. PubMed ID: 30865638
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Polysaccharide rich extract (PRE) from Tinospora cordifolia inhibits the intracellular survival of drug resistant strains of Mycobacterium tuberculosis in macrophages by nitric oxide induction.
    Gupta PK; Kulkarni S
    Tuberculosis (Edinb); 2018 Dec; 113():81-90. PubMed ID: 30514517
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A high-throughput target-based screening approach for the identification and assessment of
    Smiejkowska N; Oorts L; Van Calster K; De Vooght L; Geens R; Mattelaer H-P; Augustyns K; Strelkov SV; Lamprecht D; Temmerman K; Sterckx YG-J; Cappoen D; Cos P
    Microbiol Spectr; 2024 Mar; 12(3):e0372323. PubMed ID: 38315026
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis.
    Schaaf K; Smith SR; Hayley V; Kutsch O; Sun J
    J Vis Exp; 2017 Mar; (121):. PubMed ID: 28362407
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of potent chemical antituberculosis agents targeting Mycobacterium tuberculosis acetohydroxyacid synthase.
    Jung IP; Ha NR; Lee SC; Ryoo SW; Yoon MY
    Int J Antimicrob Agents; 2016 Sep; 48(3):247-58. PubMed ID: 27451857
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The preclinical candidate indole-2-carboxamide improves immune responses to Mycobacterium tuberculosis infection in healthy subjects and individuals with type 2 diabetes.
    Cao R; Islamoglu H; Teskey G; Gyurjian K; Abrahem R; Onajole OK; Lun S; Bishai W; Kozikowski AP; Fraix MP; Sathananthan A; Zhong L; Stec J; Venketaraman V
    Int Microbiol; 2020 May; 23(2):161-170. PubMed ID: 31218537
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Output-driven feedback system control platform optimizes combinatorial therapy of tuberculosis using a macrophage cell culture model.
    Silva A; Lee BY; Clemens DL; Kee T; Ding X; Ho CM; Horwitz MA
    Proc Natl Acad Sci U S A; 2016 Apr; 113(15):E2172-9. PubMed ID: 27035987
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of 2-hydroxy-1-naphthaldehyde isonicotinoyl hydrazone as a novel inhibitor of methionine aminopeptidases from Mycobacterium tuberculosis.
    John SF; Aniemeke E; Ha NP; Chong CR; Gu P; Zhou J; Zhang Y; Graviss EA; Liu JO; Olaleye OA
    Tuberculosis (Edinb); 2016 Dec; 101S():S73-S77. PubMed ID: 27856197
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Whole cell screen for inhibitors of pH homeostasis in Mycobacterium tuberculosis.
    Darby CM; Ingólfsson HI; Jiang X; Shen C; Sun M; Zhao N; Burns K; Liu G; Ehrt S; Warren JD; Andersen OS; Brickner SJ; Nathan C
    PLoS One; 2013; 8(7):e68942. PubMed ID: 23935911
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Direct detection of Mycobacterium tuberculosis and drug resistance in respiratory specimen using Abbott Realtime MTB detection and RIF/INH resistance assay.
    Tam KK; Leung KS; To SW; Siu GK; Lau TC; Shek VC; Tse CW; Wong SS; Ho PL; Yam WC
    Diagn Microbiol Infect Dis; 2017 Oct; 89(2):118-124. PubMed ID: 28780247
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel high throughput pooled shRNA screening identifies NQO1 as a potential drug target for host directed therapy for tuberculosis.
    Li Q; Karim AF; Ding X; Das B; Dobrowolski C; Gibson RM; Quiñones-Mateu ME; Karn J; Rojas RE
    Sci Rep; 2016 Jun; 6():27566. PubMed ID: 27297123
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Linking High-Throughput Screens to Identify MoAs and Novel Inhibitors of Mycobacterium tuberculosis Dihydrofolate Reductase.
    Santa Maria JP; Park Y; Yang L; Murgolo N; Altman MD; Zuck P; Adam G; Chamberlin C; Saradjian P; Dandliker P; Boshoff HIM; Barry CE; Garlisi C; Olsen DB; Young K; Glick M; Nickbarg E; Kutchukian PS
    ACS Chem Biol; 2017 Sep; 12(9):2448-2456. PubMed ID: 28806050
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An in vivo platform for rapid high-throughput antitubercular drug discovery.
    Takaki K; Cosma CL; Troll MA; Ramakrishnan L
    Cell Rep; 2012 Jul; 2(1):175-84. PubMed ID: 22840407
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of glucosyl-3-phosphoglycerate phosphatase as a novel drug target against resistant strain of Mycobacterium tuberculosis (XDR1219) by using comparative metabolic pathway approach.
    Uddin R; Zahra NU; Azam SS
    Comput Biol Chem; 2019 Apr; 79():91-102. PubMed ID: 30743161
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potential and development of inhaled RNAi therapeutics for the treatment of pulmonary tuberculosis.
    Man DK; Chow MY; Casettari L; Gonzalez-Juarrero M; Lam JK
    Adv Drug Deliv Rev; 2016 Jul; 102():21-32. PubMed ID: 27108702
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potential use of nitrate reductase as a biomarker for the identification of active and dormant inhibitors of Mycobacterium tuberculosis in a THP1 infection model.
    Sarkar S; Sarkar D
    J Biomol Screen; 2012 Aug; 17(7):966-73. PubMed ID: 22573731
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tuberculosis drugs: new candidates and how to find more.
    Sala C; Hartkoorn RC
    Future Microbiol; 2011 Jun; 6(6):617-33. PubMed ID: 21707310
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.
    Cho SH; Warit S; Wan B; Hwang CH; Pauli GF; Franzblau SG
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1380-5. PubMed ID: 17210775
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.